tbuckley/cabot-search huggingface dataset:
Abstract P3-07-60: Impact of high SPARC expression of a primary tumor as a strong risk factor for disease recurrence and overall survival in patients with triple-negative breast cancer
Authors: A Zhu, P Yuan, F Du, X Ding, B Xu
Journal: Cancer Research (2016)

Abstract Background: SPARC (secreted protein acidic and rich in cystein) is a secreted glycoprotein that interacts with extracellular matrix protein and acts as a regulator of critical cellular functions such as proliferation and cell migration. An increasing number of studies have shown altered expression of SPARC in several malignancies. However, the role of this potential biomarker in breast cancer development and progression is controversial. Triple-negative breast cancer (TNBC) is known for its poor prognosis and high recurrence probability. There is a need for prognostic biomarkers to guide treatment decisions for this subtype. Objective: To explore the association between SPARC and the prognosis of triple-negative breast cancer. Methods: In this study, a total of 211 samples of triple-negative breast lesions from 2004 to 2008 were collected in Cancer Hospital, Chinese Academy of Medical Sciences. SPARC expression was evaluated by immunohistochemistry using an immunoreactive score (IRS) from patients with up to 10 years clinical follow-up data. The current study set out to examine both the expression of SPARC in primary tumor tissue and to demonstrate if a link existed between the levels of SPARC and the clinical outcome. Cox proportional hazards model was used to estimate HRs and 95%CI, stratified on tumor grade, TNM stage, lymph node status and vascular invasion. Results: High SPARC expression (IRS≥3) was observed in 52.1% of all primary tumors. Patients expressing low levels of SPARC had better disease-free survival (DFS) (HR=0.632, 95%CI:0.405-0.987, P = 0.044) as well as overall survival(OS)(HR=0.576, 95%CI:0.351-0.946, P = 0.029) compared to those with high SPARC expression levels.Furthermore, the presence of high SPARC expression was an independent prognostic factor for both DFS (HR=1.67, 95%CI:1.04-2.69, P=0.034) and OS(HR=1.77, 95%CI:1.04-3.01, P=0.037) of triple-negative breast cancer patients, stratified on tumor grade, TNM stage, lymph node metastasis and vascular invasion, with adjustment for age, hormonal status, tumor size, adjuvant radiotherapy and adjuvant chemotherapy. Conclusion: Our results suggest that the presence of higher SPARC expression could be an indicator of high aggressiveness and may be a strong prognostic factor for triple-negative breast cancer. Citation Format: Zhu A, Yuan P, Du F, Ding X, Xu B. Impact of high SPARC expression of a primary tumor as a strong risk factor for disease recurrence and overall survival in patients with triple-negative breast cancer. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P3-07-60.
Effect of ipilimumab treatment on 18-month survival: Update of patients (pts) with advanced melanoma treated with 10 mg/kg ipilimumab in three phase II clinical trials
Authors: S. O'Day, J. Weber, C. Lebbe, M. Maio, H. Pehamberger, K. Harmankaya, J. Siegel, A. Hoos, R. Humphrey, J. Wolchok
Journal: Journal of Clinical Oncology (2009)

9033 Background: The monoclonal antibody ipilimumab targets cytotoxic T lymphocyte antigen-4. Updated survival data (≤32.5 months follow-up) from 3 Phase II trials of ipilimumab in pts with mostly pretreated advanced melanoma are reported. Methods: Study CA184008 was an open-label, single-arm study of ipilimumab 10 mg/kg. Study CA184022 was a randomized, dose-ranging study of ipilimumab 0.3, 3, or 10 mg/kg. Study CA184007 was a randomized, placebo-controlled study of the effect of budesonide on gastrointestinal immune-related adverse events in pts receiving ipilimumab 10 mg/kg. In all studies, ipilimumab was given every 3 weeks (Q3W) × 4 (induction); eligible pts could continue to receive maintenance ipilimumab Q12W from week 24. Pts continue to be followed-up to determine long-term survival. Results: With a median follow-up ranging from 10.1 to 16.3 months and reaching up to 32.5+ months, pts receiving 10 mg/kg ipilimumab showed durable survival; 12- and 18-month survival rates are presented [ Table ]. The tail of the Kaplan-Meier curve flattened at 18 months, indicating that a substantial proportion of patients continued to survive beyond the updated follow-up period in all three studies. Long-term survivors include pts with disease progression (PD) per modified World Health Organization (mWHO) criteria. Conclusions: Ipilimumab may result in a long-term survival benefit in pts with advanced melanoma, where 18-month survival rates across 3 Phase II studies range from 34.5% to 39.4% for previously treated pts. These results indicate that more than 1/3 of ipilimumab-treated pts with advanced melanoma experience a long-term survival benefit, including some pts characterized as PD by mWHO. The survival data continue to mature, and follow-up is ongoing. [Table: see text] [Table: see text]
Characteristics of childhood cancer survivors who attend long-term follow-up (LTFU) clinic.
Authors: K. Devine, J. R. Andolina, N. Murray, G. R. Morrow, O. J. Sahler
Journal: Journal of Clinical Oncology (2011)

9566 Background: Although the Children’s Oncology Group developed LTFU guidelines for childhood cancer survivors, the majority of adult survivors do not receive risk-based care through a LTFU program. This study aimed to identify characteristics of pediatric cancer survivors who return to a LTFU Clinic for care compared with patients who do not. Methods: Chart review of patients eligible to be seen in the LTFU Clinic who completed treatment between 1/1990 and 11/2010. Patient characteristics (demographics, school functioning, high-risk behaviors such as using drugs, alcohol, cigarettes) and treatment characteristics (diagnosis, treatment) were abstracted from medical records. Review of 137 charts so far revealed that eligible patients ranged in age from 6 to 37 years (M = 22.5, SD = 6.8), were 52.6% male, 88.3% Caucasian, and completed treatment about 13 years earlier. Point biserial correlations and Chi-square analyses were used to determine associations between patient and treatment characteristics and LTFU attendance. Results: 46.7% of patients had attended LTFU Clinic within 2 years of their last recommended follow-up. Current age was significantly inversely associated with current attendance, rpb = -.47, p < .001. Similarly, patients aged >18 were less likely to be current compared with patients <18, χ2(1) = 30.45, p < .001. There were no significant differences based on treatment received (surgery, radiation, chemotherapy), risk status for late effects, or documented late effects. Patients were less likely to be current if they had a documented psychiatric disorder (e.g., depression, anxiety), χ2(1) = 5.79, p = .016 or had reported past or ongoing drug use, χ2(1) = 4.68, p = .031. For patients >18 at last visit, there was a non-significant trend suggesting those who were married were more likely to be current, χ2(1) = 2.83, p = .09. Conclusions: Adult survivors of childhood cancer are less likely than younger counterparts to participate in recommended LTFU at a pediatric institution. Significant factors associated with current attendance included age and psychosocial issues, such as documented psychiatric problems and drug use. Patients like these may require additional monitoring to promote engagement in LTFU care.
ACY-1215, a Selective Histone Deacetylase (HDAC) 6 Inhibitor, In Combination With Lenalidomide and Dexamethasone (dex), Is Well Tolerated Without Dose Limiting Toxicity (DLT) In Patients (Pts) With Multiple Myeloma (MM) At Doses Demonstrating Biologic Activity: Interim Results Of a Phase 1b Trial
Authors: Andrew Yee, Peter Vorhees, William I. Bensinger, Jesus Berdeja, Jeffrey G Supko, Paul G. Richardson, Simon S Jones, Gretchen Patrick, Catherine Wheeler, Noopur Raje
Journal: Blood (2013)
Systemic Sclerosis (Scleroderma).
Journal: Annals of Internal Medicine (1985)

Systemic sclerosis (SSc) is an autoimmune systemic disease characterized by small vessel involvement that leads to tissue ischemia and fibroblast stimulation resulting in accumulation of collagen (fibrosis) in the skin and internal organs. The peak incidence of the disease is found between the third and fifth decade of life. The male to female ratio is 5:1. Annual incidence is 14.1 cases per million. Prevalence ranges from 19 to 75 cases per million. No well-defined treatment has been found. However several types of treatment exist and can be classified as such A) systemic therapies and B) organ - specific therapies. Systemic therapies are subdivided into vascular therapies, immunomodulating therapies and antifibrotic therapies. Organ-specific therapies are subdivided into therapy of pulmonary interstitial fibrosis, therapy of pulmonary hypertension, therapy of SSc renal crisis. Most of the above-mentioned therapies have been tested in open clinical trials. Systemic sclerosis is more common in coal and gold miners and miners exposed to vinyl-chloride, epoxyresins and aromatic hydrocarbons. However, these factors do not explain the spontaneously developed disease. Recently, CD34 stem cells of child origin were detected in women with SSc more commonly than in normal women. Furthermore, the SSc women display histocompatibility in most of the HLA loci with their children.
PWE-157 Reducing anastomotic leak rate in ivor lewis oesophagectomy – testing a change from mechanical to semi-mechanical anastomosis
Authors: J Clark, G Sanders, T Wheatley, P Peyser, J Rahamim, G Gangandeep, R Berrisford
Journal: Gut (2015)

<h3>Introduction</h3> The reduction in mortality after oesophagectomy seen over the last decade has not been matched by a reduction in anastomotic leaks with a leak rate of 5–10% accepted as a standard of care. Leaks increase postoperative mortality, morbidity and length of stay and reduce cancer survival. We present the results of a modified semi-mechanical intrathoracic anastomotic technique (SM) originally described by Orringer <i>et al</i><sup>1</sup>for the cervical anastomosis. <h3>Method</h3> Centralisation of oesophagogastric cancer surgery took place in our region in January 2010, bringing together five surgeons from three surgical units. For consistency, all five surgeons used a standard circular stapled anastomotic technique (CS) from 2010, but the leak rate was deemed too high. As a result, three of the five surgeons (A, B, and C) changed to a modified SM technique (surgeon A changed in November 2011, surgeon B in December 2011 and surgeon C in May 2013). This anastomosis joins the obliquely cut end of the oesophagus to the side of the proximal gastric conduit with a single 25 mm firing of a 45 mm linear stapler posteriorly (ATS45, Blue cartridge, Ethicon), the remainder of the anastomosis being completed with single layer inverting interrupted 3/0 PDS. The other two surgeons (D and E) continued to use the CS technique. Anastomotic leak rates, mortality and length of stay were evaluated to test this change in technique. <h3>Results</h3> Between Jan 2010 and February 2015 inclusive 376 patients underwent curative intent, 2-stage Ivor Lewis oesophagectomy for cancer. One patient died in hospital (0.27% mortality). The anastomotic leak rate Surgeons A, B and C using CS was 16.8%(15/92) and SM 0.8%(1/127) for surgeons D and E the rate was 10.2%(16/157). The median post-operative length of stay between groups was 11(7–56), 10(6–58) and 12(7–51) respectively. <h3>Conclusion</h3> There was a profound reduction in anastomotic leak rate for all three surgeons who changed from circular to semi-mechanical anastomosis. <h3>Disclosure of interest</h3> None Declared. <h3>Reference</h3> Orringer MB, <i>et al</i>. Eliminating the cervical esophagogastric anastomotic leak rate with a side to side stapled anastomosis. <i>J Thorac Cardiovasc Surg</i>. 2000 Feb;119(2):277-88
Predicting LVOT Obstruction After TMVR
Authors: Dee Dee Wang, Marvin Eng, Adam Greenbaum, Eric Myers, Michael Forbes, Milan Pantelic, Thomas Song, Christina Nelson, George Divine, Andrew Taylor, Janet Wyman, Mayra Guerrero, Robert J. Lederman, Gaetano Paone, William O’Neill
Journal: JACC. Cardiovascular imaging (2016)
Early Azithromycin Treatment to Prevent Severe Lower Respiratory Tract Illnesses in Children
Authors: Katherine E. Fleming-Dutra, Cindy R. Friedman, Lauri A. Hicks
Journal: JAMA (2016)

The study by Dr Bacharier and colleagues1 found that using azithromycin in preschool children with a history of wheezing and respiratory tract infection (RTI) prevented progression to “severe” lower respiratory tract illness (LRTI). The authors defined severe LRTI as needing intensive rescue albuterol treatments; it was not defined as pneumonia, the classic definition of severe LRTI. Although azithromycin limited the need for intensive rescue albuterol, it did not prevent urgent care or emergency visits, hospitalizations, or future RTI episodes, arguably the most important prevention outcomes.
NANS-mediated synthesis of sialic acid is required for brain and skeletal development
Authors: Clara D M van Karnebeek, Luisa Bonafé, Xiao-Yan Wen, Maja Tarailo-Graovac, Sara Balzano, Beryl Royer-Bertrand, Angel Ashikov, Livia Garavelli, Isabella Mammi, Licia Turolla, Catherine Breen, Dian Donnai, Valérie Cormier-Daire, Delphine Heron, Gen Nishimura, Shinichi Uchikawa, Belinda Campos-Xavier, Antonio Rossi, Thierry Hennet, Koroboshka Brand-Arzamendi, Jacob Rozmus, Keith Harshman, Brian J Stevenson, Enrico Girardi, Giulio Superti-Furga, Tammie Dewan, Alissa Collingridge, Jessie Halparin, Colin J Ross, Margot I Van Allen, Andrea Rossi, Udo F Engelke, Leo A J Kluijtmans, Ed van der Heeft, Herma Renkema, Arjan de Brouwer, Karin Huijben, Fokje Zijlstra, Torben Heise, Thomas Boltje, Wyeth W Wasserman, Carlo Rivolta, Sheila Unger, Dirk J Lefeber, Ron A Wevers, Andrea Superti-Furga
Journal: Nature Genetics (2016)
Use mefloquine for UK troops only as “last resort,” MPs tell Ministry of Defence
Authors: Caroline White
Journal: BMJ (2016)

British military personnel should be given the antimalarial drug mefloquine (which is marketed in the United Kingdom as Lariam) only as a “last resort,” MPs have concluded.1

In a report into the use of the drug among the armed forces, the House of Commons Defence Committee accused the Ministry of Defence of displaying a “lamentable weakness in [its] duty of care towards service personnel” and of ignoring the “stringent conditions” for safe prescribing set out by the drug’s manufacturer, Roche.

“We see no reason to disbelieve the very strong anecdotal evidence that such conditions have been ignored in dispensing it to large numbers of troops about to be deployed. Indeed, it is hard to see how they could ever be met except when the numbers …
Abstract ES3-3: Post-mastectomy breast reconstruction: defining the effects of adjuvant treatment modalities on surgical outcomes
Authors: H Sbitany
Journal: Cancer Research (2016)

Abstract Post-mastectomy breast reconstruction is routinely offered immediately at the time of mastectomy, and can be performed using prosthetic or autologous techniques. Successful surgical outcomes are routine with these procedures, but can be complicated when adjuvant treatment modalities for breast cancer are employed. The most common adjuvant treatments effecting outcomes in post-mastectomy breast reconstruction are radiation, chemotherapy/hormonal therapy, and axillary lymph node dissection. Adjuvant radiation therapy has been shown to increase the complication rate in prosthetic breast reconstruction, specifically with increased rates of implant infection (22%, p=0.0), full-thickness mastectomy skin necrosis (11.5%, p=.001), and expander/implant removal (17.7%, p=0.0). Such complication rates are improvements over earlier reports, likely due to altered incision placement in nipple sparing mastectomy to the periareolar area, waiting at least 6 months following radiation completion prior to implant exchange, and the use of acellular dermal matrices (shown on multivariate analysis to reduce explantation rates in setting of radiation). With autologous breast reconstruction, adjuvant radiation has been shown to increase rates of volume flap volume loss (19.75%, p=.0001), but not flap loss rates (1.23%, p=1). The use of adjuvant chemotherapy and hormonal therapy has not been shown to negatively impact outcomes in prosthetic breast reconstruction, to any statistically significant amount. This includes tamoxifen and herceptin therapy. Similarly, the use of hormonal therapy does not significantly effect overall outcomes in autologous breast reconstruction. The use of axillary lymph node dissection has been shown to have a significant negative impact on outcomes in prosthetic breast reconstruction, compared to sentinel lymph node biopsy. On multivariate analysis, axillary lymph node dissection increased rates of breast implant loss (RR 2.0, p=.021), relative to sentinel lymph node biopsy. This is due to the decreased lymphatic drainage of remaining breast tissue, and resultant increase in infection and implant loss. Citation Format: Sbitany H. Post-mastectomy breast reconstruction: defining the effects of adjuvant treatment modalities on surgical outcomes. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr ES3-3.
On the So-Called “Thiamin-Destructive Influence” by the Saliva of Patients with Cancer or Other Disease
Authors: Tatsuhei Kondo, Hideo Sakakibara, Tadao Iida
Journal: JNCI Journal of the National Cancer Institute (1956)

Journal Article On the So-Called “Thiamin-Destructive Influence” by the Saliva of Patients with Cancer or Other Disease Get access Tatsuhei Kondo, Tatsuhei Kondo from the Second Department of Surgery, Nagoya University School of Medicine (Director: Professor Hajime Imanaga), Nagoya, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar Hideo Sakakibara, Hideo Sakakibara from the Second Department of Surgery, Nagoya University School of Medicine (Director: Professor Hajime Imanaga), Nagoya, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar Tadao Iida Tadao Iida from the Second Department of Surgery, Nagoya University School of Medicine (Director: Professor Hajime Imanaga), Nagoya, Japan Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 16, Issue 4, February 1956, Pages 971–980, https://doi.org/10.1093/jnci/16.4.971 Published: 01 February 1956 Article history Published: 01 February 1956 Received: 01 February 1964
Abstract P1-07-22: Infectious disease hospitalization in breast cancer patients: Risk and impact on prognosis
Authors: JS Brand, E Colzani, A Johansson, J Giesecke, M Clements, J Bergh, P Hall, K Czene
Journal: Cancer Research (2016)

Abstract Background: Infection-related hospitalizations are a serious complication in breast cancer patients, resulting in treatment delay, prolonged hospitalization and future morbidity and mortality. Little, however, is known about the actual risk, clinical characteristics and outcomes of infection-related hospitalizations in this patient population. Methods: We conducted a prospective population-based study including 7071 women diagnosed with primary invasive non-metastatic breast cancer between 2001 and 2008 in the Stockholm-Gotland region (Sweden), with complete follow-up until 2010. Standardized incidence ratios (SIRs) for infection-related hospitalizations (overall and by site) were estimated using background rates from the general female population, matched on age and calendar period. Associations with clinical characteristics and breast cancer outcomes (breast cancer death, distant metastasis and locoregional recurrence) were analysed using flexible parametric survival models. Results: During a medium follow-up of 5.3 years, 657 hospital admissions with infections were observed and 1,2 and 5-year cumulative risks were 3.4, 4.7 and 8.1% respectively. Rates of infection-related hospitalizations were increased compared to the general female population (SIR = 2.12; 95% CI = 1.96-2.29) and site-specific SIRs were most pronounced for sepsis (SIR = 3.65; 95% CI = 3.13-4.26) and skin infections (SIR = 2.93; 95% CI = 2.35-3.64). The overall risk of infections was highest during the first year (SIR = 5.06; 95% CI, 4.46-5.74), and recurrent disease contributed to the long-term risk observed. Older age at diagnosis, chemotherapy, axillary radiotherapy, comorbidities and markers of tumor aggressiveness (large tumors, estrogen receptor negative tumors and lymph node positive tumors) were independent predictors of infectious disease risk. Analyses evaluating the prognostic impact of infections revealed an independent effect on breast cancer death and distant metastasis, associations that were mainly driven by sepsis (HR = 4.53; 95% CI, 3.25-6.33 and 1.69; 95% CI, 1.04-2.79 respectively). No association was found with future risk of locoregional recurrence. Conclusions: Physicians and patients should be aware of the risk of serious infections which persists beyond the initial treatment period. Infection-related hospitalizations are an independent marker of poor prognosis. Further research is needed to elucidate the role of sepsis in breast cancer progression. Citation Format: Brand JS, Colzani E, Johansson A, Giesecke J, Clements M, Bergh J, Hall P, Czene K. Infectious disease hospitalization in breast cancer patients: Risk and impact on prognosis. [abstract]. In: Proceedings of the Thirty-Eighth Annual CTRC-AACR San Antonio Breast Cancer Symposium: 2015 Dec 8-12; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2016;76(4 Suppl):Abstract nr P1-07-22.